All In MedTech

FDA Clearance Tracker · P000025-S063

MED-EL COCHLEAR IMPLANT SYSTEMS (COMBI40+, PULSARCI100, SONATATI100, MED-EL CONCERT, & MED-EL CONCERT PIN)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 6, 2013 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 6, 2013

Approved

Time to decision

300 days

Received Aug 10, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000025-S063
Device name
MED-EL COCHLEAR IMPLANT SYSTEMS (COMBI40+, PULSARCI100, SONATATI100, MED-EL CONCERT, & MED-EL CONCERT PIN)
Applicant
Med-El Corp.
Applicant location
Innsbruck
Received
Aug 10, 2012
Decided
Jun 6, 2013
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P000025

Device type

Device class
Class III

Every decision under product code MCM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR NEW LABELING THAT DESCRIBES CONDITIONS FOR SAFE MAGNETIC RESONANCE (MR) IMAGING AT 0.2 AND 1.5 TESLA FIELD STRENGTHS AND RADIATION THERAPY OF PATIENTS IMPLANTED WITH THE MED-EL COCHLEAR IMPLANT SYSTEMS WHICH INCLUDE THE PULSARCI100, SONATATI100, MED-EL CONCERT, MED-EL CONCERT PIN IMPLANTS.

Source documents

Other decisions for Med-El Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.